Cognoa announced that its first digital diagnostic and digital therapeutic devices to treat autism have received Breakthrough Device designations from the FDA.
Cognoa, located in Palo Alto CA, is developing methods for evaluating a subject for a developmental condition that can be tuned to control the tradeoff between coverage and reliability. Cognoa is also developing a digital personalized medicine system that uses digital data to assess or diagnose symptoms of a subject to provide personalized therapeutic interventions and improved diagnoses.